Medicare AdvantageDocumentationMedium impact
MA08.120e, Nivolumab (Opdivo®), Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig™)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Mar 24, 2025
We identified it
Jun 19, 2026
Summary
Policy MA08.120e updates medical necessity criteria, medical coding guidelines, and general informational content for Nivolumab (Opdivo®) and Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig™). This recent Medicare Advantage policy change affects how these immunotherapy drugs are authorized, coded, and billed. Billing teams must review updated medical necessity criteria and coding requirements to ensure compliant claim submission.
Action Required
By March 24, 2025: Billing and clinical teams must review the full policy text at the provided URL to identify specific medical necessity criteria updates and coding changes for Nivolumab (Opdivo®) and Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig™). Update prior authorization templates, billing software rules, and provider documentation requirements in the EMR to reflect new criteria. Communicate changes to oncology providers and billing staff handling immunotherapy claims. Ensure all future claims for these drugs comply with updated coding and medical necessity standards. Claims submitted without adherence to new requirements may be denied or delayed.